Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/136334
Full metadata record
DC FieldValueLanguage
dc.creatorTrovão, N
dc.creatorPrata, J
dc.creatorVondoellinger, O
dc.creatorSantos, SG
dc.creatorBarbosa, MA
dc.creatorCoelho, R
dc.date.accessioned2021-09-20T10:53:12Z-
dc.date.available2021-09-20T10:53:12Z-
dc.date.issued2019
dc.identifier.issn1738-3684
dc.identifier.urihttps://hdl.handle.net/10216/136334-
dc.description.abstractObjective Schizophrenia is a disabling disorder of unknown aetiology, lacking definite diagnostic method and cure. A reliable biological marker of schizophrenia is highly demanded, for which traceable immune mediators in blood could be promising candidates. We aimed to gather the best findings of neuroinflammatory markers for first-episode psychosis (FEP). Methods We performed an extensive narrative review of online literature on inflammation-related markers found in human FEP patients only. Results Changes to cytokine levels have been increasingly reported in schizophrenia. The peripheral levels of IL-1 (or its receptor antagonist), soluble IL-2 receptor, IL-4, IL-6, IL-8, and TNF-a have been frequently reported as increased in FEP, in a suggestive continuum from high-risk stages for psychosis. Microglia and astrocytes establish the link between this immune signalling and the synthesis of noxious tryptophan catabolism products, that cause structural damage and directly hamper normal neurotransmission. Amongst these, only 3-hydroxykynurenine has been consistently described in the blood of FEP patients. Conclusion Peripheral molecules stemming from brain inflammation might provide insightful biomarkers of schizophrenia, as early as FEP or even prodromal phases, although more timeand clinically-adjusted studies are essential for their validation.
dc.description.sponsorshipThis work has been conducted with the support of the Portuguese Foundation for Science and Technology.
dc.language.isoeng
dc.publisherKorean Neuropsychiatric Association
dc.relation.ispartofPsychiatry Investigation, vol.16(3), p. 177-184
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectBiomarkers
dc.subjectFirst-episode psychosis
dc.subjectImmune
dc.subjectNeuroinflammation
dc.subjectSchizophrenia
dc.titlePeripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.30773/pi.2018.12.19.1
dc.relation.publisherversionhttps://www.psychiatryinvestigation.org/journal/view.php?doi=10.30773/pi.2018.12.19.1
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.30773-pi.2018.12.19.1.pdf469.99 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons